Medical News Podcast

A trial found that discontinuing beta-blockers in stable post-MI patients without heart failure was noninferior to continuing them, suggesting long-term use may be unnecessary. Second, the 2026 ACC/AHA lipid guideline promotes earlier, personalized intervention using the PREVENT risk calculator and expanded biomarkers to reduce lifetime cardiovascular risk. Finally, a JAMA study found thiazide diuretics carry meaningful hyponatremia risk, especially in older adults and women, urging careful patient selection

Drs. Swigris and Humphries discuss how AI-driven, quantitatively trained algorithms can standardize the interpretation of high-resolution computed tomography (HRCT) in ILD by reducing inter- and intra-reader variability and improving fibrosis extent assessment. They contrast traditional visually based radiology with supervised machine learning approaches, including models trained on biopsy-confirmed diagnoses and disease behavior, to potentially enhance prognostication and clinical decision-making.

A randomized trial in the New England Journal of Medicine found prehospital whole blood transfusion did not improve 30-day mortality over standard component therapy in traumatic hemorrhage, supporting current transfusion protocols. A large population-based study showed patients with positive fecal occult blood tests who did not complete follow-up colonoscopy had significantly higher colorectal cancer incidence and more advanced-stage disease. Finally, a study in Nature Medicine of nearly 15,000 individuals found antibiotic exposure reduced gut microbial diversity for up to 4–8 years, with clindamycin and fluoroquinolones causing the most persistent disruption.

Drs. Sanossian and Saver review new evidence supporting intensified antithrombotic strategies to reduce recurrent ischemic stroke in high-risk, noncardioembolic patients without increasing intracranial hemorrhage. They place this within a comprehensive, multimodal secondary prevention framework that integrates pharmacologic therapy with aggressive risk factor modification (lipids, blood pressure, diabetes, and lifestyle).

Drs. O’Brien and Wierda discuss how fixed-duration venetoclax-based therapy can match continuous BTK inhibitor treatment in CLL while offering deep remissions and time off therapy. They also explore promising real-world CAR T-cell (liso-cel) results and stress the growing importance of vaccination and cancer screening as CLL patients live longer.

Drs. Dougherty and Ailani discuss the 2025 International Headache Society guidelines indicating that neuromodulation is an effective, non-invasive option for both acute and preventive migraine treatment. They stress that it works best as part of a personalized, multimodal plan alongside medications, behavioral therapies, and lifestyle changes.

Drs. Maron and Rowin provide an overview of hypertrophic cardiomyopathy, explaining how it is diagnosed by heart imaging and classified into obstructive and non-obstructive forms. They highlight that obstruction is a major cause of symptoms and stress the importance of carefully assessing patients’ day-to-day limitations to guide treatment decisions.

Drs. Petri and Woolfson discuss a simple risk score using autoantibodies, complement, and demographics to predict which SLE patients are most likely to develop proteinuria and lupus nephritis. They also highlight evidence showing that earlier kidney biopsies at lower proteinuria levels, especially in patients with low complement, can detect serious disease sooner and improve outcomes.

This week's podcast covers three NEJM trials. First, apixaban showed over 50% less clinically relevant bleeding than rivaroxaban in acute venous thromboembolism patients, with similar efficacy. Second, romiplostim helped 84% of patients on oxaliplatin-based chemotherapy avoid dose modifications due to thrombocytopenia, versus 36% with placebo. Third, inhaled treprostinil slowed lung function decline in idiopathic pulmonary fibrosis patients over 52 weeks, though cough and discontinuation rates were higher.

Drs. Isaacs and Traina discuss DESTINY-Breast09, where first‑line T‑DXd + pertuzumab clearly outperforms the CLEOPATRA regimen in progression-free survival for metastatic HER2+ breast cancer. They focus on the dilemma of when to use T‑DXd: earlier, for maximal efficacy, or later, to protect quality of life and manage ILD and cardiac risks.

This week's podcast covers three NEJM trials. First, apixaban showed over 50% less clinically relevant bleeding than rivaroxaban in acute venous thromboembolism patients, with similar efficacy. Second, romiplostim helped 84% of patients on oxaliplatin-based chemotherapy avoid dose modifications due to thrombocytopenia, versus 36% with placebo. Third, inhaled treprostinil slowed lung function decline in idiopathic pulmonary fibrosis patients over 52 weeks, though cough and discontinuation rates were higher.

Drs. Cytryn, Foote, and Thummalapalli review evolving HER2-targeted treatment strategies for upper GI, biliary, and colorectal cancers, emphasizing challenges with disease heterogeneity and treatment sequencing. They also highlight the importance of HER2 reassessment after progression and advancing diagnostic approaches.

Three studies highlight new findings: A phase 3 trial showed obinutuzumab significantly improved lupus responses versus placebo in active SLE patients on standard therapy. A trial of finerenone in type 1 diabetes with chronic kidney disease demonstrated meaningful reductions in albuminuria compared to placebo, suggesting a new renal-protective option. Finally, paired pediatric trials found that adding acetaminophen or hydromorphone to ibuprofen provided no additional pain relief for children's acute limb injuries, with opioids causing four times more adverse events. Ibuprofen alone remains the recommended first-line approach.

Drs. Isaacs and Traina review how HER2CLIMB‑05 and PATINA challenge the old CLEOPATRA‑based approach by showing that adding tucatinib or palbociclib to maintenance therapy can extend progression‑free survival in metastatic HER2+ breast cancer. They stress tailoring maintenance regimens to each patient’s hormone receptor status, CNS risk, and tolerance for side effects.

Drs. Isaacs and Traina review how HER2CLIMB‑05 and PATINA challenge the old CLEOPATRA‑based approach by showing that adding tucatinib or palbociclib to maintenance therapy can extend progression‑free survival in metastatic HER2+ breast cancer. They stress tailoring maintenance regimens to each patient’s hormone receptor status, CNS risk, and tolerance for side effects.

Drs. Petri and Woolfson review the American College of Rheumatology Convergence 2025 data that suggest belimumab might lower mortality in SLE compared with traditional oral immunosuppressants, supporting earlier biologic use. They also discuss an observational study in lupus nephritis that links GLP-1 agonists to better kidney, survival, and cardiovascular outcomes than SGLT2 inhibitors, particularly in overweight patients.

Drs. Vakharia and Danzig highlight new AAO 2025 data on high-dose aflibercept, sleep apnea as a potential AMD risk factor, and an AI-guided anti-VEGF regimen that cuts injections while maintaining vision. Together, these advances point toward more personalized, efficient care for patients with neovascular AMD and DME.

Oral semaglutide reduced heart failure hospitalizations and cardiovascular death in type 2 diabetes patients with existing heart failure, particularly those with preserved ejection fraction, but showed no benefit in those without baseline heart failure. Modern total hip replacements demonstrate excellent longevity, with over 92% of implants surviving revision-free at 30 years. A pharmacist-led opioid and benzodiazepine tapering program in older adults showed no significant advantage over usual care.

Drs. Isaacs and Traina discuss new data in HER2+ breast cancer from the 2025 San Antonio Breast Cancer Symposium, focusing on early-stage studies including DESTINY-Breast11 and DESTINY-Breast05 and how data from these studies could potentially impact patient care in the future.

Drs. Wierda and O’Brien discuss emerging data showing the non-covalent BTK inhibitor pirtobrutinib outperforming traditional chemoimmunotherapy and showing favorable efficacy and safety versus ibrutinib in CLL. They also highlight promising early results from a triplet regimen for Richter transformation, suggesting the best survival outcomes yet seen in this historically high‑risk, hard‑to-treat population.